EMA starts review of Novavax COVID vaccine
The European Medicines Agency (EMA) said on Wednesday that it received and began evaluating Novavax’s application for conditional marketing authorization of its COVID-19 vaccine, Nuvaxovid.
The agency added it will conduct the review “under an accelerated timeline,” stressing approval could be granted in a matter of weeks in case the data the company submitted are “sufficiently robust and complete to show the efficacy, safety and quality of the vaccine.”
“Today’s announcement from EMA brings Novavax another step closer to our goal of ensuring broad global access to our protein-based COVID-19 vaccine across Europe,” Novavax CEO Stanley Erck commented on the news.
Get involved!
Comments